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Abstract
Hepatitis C virus (HCV) infection is a major public health burden in Europe, causing an increasing level of
liver-related morbidity and mortality, characterized by several regional variations in the genotypes distribution.
A comprehensive review of the literature from 2000 to 2015 was used to gather country-specific data on
prevalence and genotype distribution of HCV infection in 33 European countries (about 80 % of the European
population), grouped in three geographical areas (Western, Eastern and Central Europe), as defined by the Global
Burden of Diseases project (GBD).
The estimated prevalence of HCV in Europe is 1.7 % showing a decrease than previously reported (− 0.6 %) and
accounting over 13 million of estimated cases. The lowest prevalence (0.9 %) is reported from Western Europe
(except for some rural areas of Southern Italy and Greece) and the highest (3.1 %) from Central Europe, especially
Romania and Russia. The average HCV viraemic rate is 72.4 %, with a population of almost 10 million of HCV RNA
positive patients.
Genotype distribution does not show high variability among the three macro-areas studied, ranging between 70.0 %
(Central Europe), 68.1 % (Eastern Europe) and 55.1 % (Western Europe) for genotype 1, 29.0 % (Western Europe), 26.6 %
(Eastern Europe) and 21.0 % (Central Europe) for genotype 3. Genotype 2 seems, instead, to have a major prevalence in
the Western Europe (8.9 %), if compared to Eastern (4.3 %) or Central (3.2 %), whereas genotype 4 is present especially
in Central and Western area (4.9 % and 5.8 %, respectively).
Despite the eradication of transmission by blood products, HCV infection continues to be one of the leading
blood-borne infections in Europe. The aim of this review is, therefore, to provide an update on the epidemiology
of HCV infection across Europe, and to foster the discussion about eventual potential strategies to eradicate it.
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Background
Hepatitis C virus (HCV) is one of the major globally
prevalent pathogen and one of the main leading cause of
death and morbidity also in Europe [1–3]. According to
some estimates, about 3–4 million people are newly
infected every year worldwide, and over 350,000 patients
yearly die due to HCV-related disorders [4]. The last
estimates of disease burden showed an increase in
seroprevalence over the last 15 years to 2.8 %, equating
to >185 million infections worldwide [5].
The severity of HCV infection is essentially due to its
long term hepatic and extrahepatic consequences [6, 7].
Persistent HCV infection is generally associated with the
development of liver cirrhosis, hepatocellular carcinoma
(HCC), liver failure, and death [8], and a significant
portion of liver transplantation in Europe is attributable
to disorders related to Chronic Hepatitis C (CHC) [9].
The limited effectiveness of treatments available until a
couple of years ago have led HCV-associated mortality
to exceed that due to the human immunodeficiency
virus (HIV) in developed countries.
The incidence of complications of CHC will not de-
cline over the next 10 years despite improved efficacy of
antiviral therapy because most patients with CHC
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remain undiagnosed [10]. In addition, the clinical impact
of some extrahepatic disorders, leading to renal, cardiac
and cerebrovascular outcomes associated with cryo-
globulinemia and diabetes, has been emphasized only
recently [4, 5, 11, 12] and traditionally neglected in
cost-effectiveness analyses.
Although a recent meta-analysis indicates the global
incidence rate of HCV infection decreasing [13], mathe-
matic models show that deaths from liver disease sec-
ondary to HCV infection will continue to increase over
the next 20 years [14, 15]. This means that, although
many data suggest that HCV infection could be eliminated
in the next 15–20 years with focused strategies to cure
current infections and prevent new infections [16, 17], a
good understanding of HCV epidemiology should be
required to develop strategies to eradicate HCV.
The epidemiological status of HCV infection in Europe
is continuously evolving and may vary significantly region
by region. In the last years several studies have re-
ported level prevalence estimates of HCV infections
in Europe, but always considering a limited number
of countries or specific risk groups [18–23]. A more
recent analysis, instead, estimates a global and also
European HCV prevalence, but provides only regional
estimates [3]. In all these cases, however, studies were
focused only on the presence of HCV antibodies that
generally overestimates the disease burden because
they include also patients healed spontaneously or
through treatments. So, although antibodies to HCV
(anti-HCV) are actually the most commonly available
marker of HCV infection and often used both to esti-
mate the prevalence of anti-HCV in population-based
studies and to compare HCV infection levels globally,
the most important indicator of HCV diffusion seems
to be its classification into different genetic variants.
HCV exhibits an extraordinarily high degree of gen-
etic diversity [24]. Its strains are classified into seven
recognized genotypes on the basis of phylogenetic and
sequence analyses of whole viral genomes [25, 26]. HCV
strains, belonging to different genotypes, differ at 30–35 %
of nucleotide sites. Within each genotype, HCV is further
classified into 67 confirmed and 20 provisional subtypes.
Strains that belong to the same subtype differ at <15 % of
nucleotide sites [27].
Since, actually, the duration of treatment and the need
for adjuvant interferon and ribavirin with the new
direct-acting antiviral (DAA) therapies still remain
dependent in part on HCV genotype and subtype, it is
clear how a better knowledge of the epidemiology of
HCV and of the distribution of its genotypes could sub-
stantially contribute to an effective control of this troub-
ling pandemic especially by focusing screening strategies
on patients at risk of disease progression, in order to get
them into earlier treatment.
Because epidemiological data are the basis for the
development of preventive strategies able to eradicate
HCV infection, the aim of this study is to systematic-
ally up-date and review HCV epidemiology throughout
Europe to foster the development of country-specific
screening programs and an international HCV surveil-
lance program.
Methods
A comprehensive review of the literature from 2000 to
2015 was used to gather country-specific data on preva-
lence, number of diagnosed individuals and genotype
distribution. References were identified through two
sources: indexed journals and non-indexed sources.
Indexed articles were found by searching Pub Med and
regional databases using the following terms: “[Country
Name] and [hepatitis c or HCV] and [prevalence]” or
[genotypes] or [viraemia]”. Furthermore, references cited
within the articles were used.
Regions included in the analysis were those defined by
the Global Burden of Diseases, Injuries, and Risk Factors
2010 (GBD) study. This study defined in Europe three
regions (Western, Eastern and Central) that were “epide-
miologically homogenous as possible so that information
from detailed studies in one country can plausibly be
extrapolated to other countries in the region to create
burden estimates that are useful to individual countries
in planning for health sector activities” [28–30].
The average HCV prevalence and viraemic rate for
each region were calculated by dividing the sum of data
reported from each country to the total number of coun-
tries within the region.
Article titles and abstracts were reviewed for relevance
and the following data were extracted from full articles
or abstracts:anti-HCV prevalence, viraemic prevalence,
viraemic rate and genotypes distribution.
Studies in non-representative populations (e.g., people
who inject drugs (PWID’s), haemophiliacs, minority eth-
nic groups, blood donors, etc.) or with a sample size of
less than 1000 and studies published prior to 2000 or
not in English were excluded from the analysis.
Five hundred twenty nine articles were selected from
33 countries based on relevance. In addition, non-
indexed sources were identified through searches of
individual country’s Ministry of Health’s websites and
international health agency reports. If articles contained
the same patient cohort then this cohort was only
counted once. No representative data were available
from six countries (Albania, Bosnia and Herzegovina,
Estonia, Iceland, Macedonia and Montenegro).
Because the first- and second generation immunoassay
tests may provide false-positive results, which can over-
estimate the total infected population, care was taken to
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use only studies that used the latest generation tests to
estimate the country’s prevalence.
In the majority of studies HCV cases were classified at
the genotype level, but not at the subtype level, so we
decided to use only genotype classification using as gen-
eral method that proposed by Simmonds et al. [25]. In
case of one or more genotypes identified in the same
patient, we classified it as “mixed”. We did not include
genotype 7 in the analysis.
General epidemiology of Hcv in Europe
The GBD subdivides Europe into 3 main areas: Central,
Eastern and Western. The collected data were segmented
by country according to prevalence, HCV genotype
distribution and viraemic rate. The European Center
for Disease Prevention and Control (ECDC) provided
incidence rates for the European countries and their
estimates were used for newly diagnosed populations
because most countries did not distinguish between
chronic and acute cases of HCV infection.
Surveillance systems also vary widely between and
within countries in Europe. A publication by ECDC
documented 38 different surveillance systems in 27
countries; six countries had more than one system [22].
Surveillance systems, besides, vary by structure, report-
ing practices, data collection methods and case defini-
tions used [31]. For these reasons, caution should be
exercised when comparing case reporting data across
countries.
The estimated prevalence of HCV of the whole continent
is 1.7 %, ranging from 3.1 % in Eastern Europe to 0.9 % in
Western Europe, accounting over 13 millions of estimated
cases. The average HCV viraemic rate is 71.3 %, with a
population of almost 10 million of HCV RNA positive
patients (Table 1).
The predominant genotype is genotype 1 (G1) (64.4 %),
followed by genotype 3 (G3) (25.5 %), 2 (G2) (5.5 %) and 4
(G4) (3.7 %). Only small percentages of genotype 5 (G5),
genotype 6 (G6) and mixed or not further classified geno-
types are reported (Table 2).
Genotype distribution does not show high variability
among the three macro-areas studied, ranging between
70.0 % (Central Europe), 68.1 % (Eastern Europe) and
55.1 % (Western Europe) for G1, 29.0 % (Western
Europe), 26.6 % (Eastern Europe) and 21.0 % (Central
Europe) for G3.
G2 seems to have a major prevalence in the Western
Europe (8.9 %), if compared to Eastern (4.3 %) or
Central (3.2 %), whereas G4 is present especially in
Central and Western area (4.9 % and 5.8, respectively).
Only few cases of G5 and G6 are reported and mainly
from Western area (Table 2).
Central Europe
This large area, including countries like Albania,
Bulgaria, Bosnia and Herzegovina, Czech Republic,
Croatia, Hungary, Macedonia, Montenegro, Poland,
Romania, Serbia, Slovakia and Slovenia, shows a
prevalence of HCV infection of 1.2 %, varying between
3.2 % in Romania and 0.5 % in Serbia and an average
viraemic rate estimated at 73.3 % (Table 3). We did
not found representative data concerning the HCV
prevalence from published studies in Albania, Bosnia
and Herzegovina, Macedonia and Montenegro.
The predominant genotypes in this area is G1
(70.0 %), followed by G3 (21.0 %), G4 (4.9 %) and G2
(3.2 %). Only a small percentage of mixed genotypes and
G6 has been found, whereas no G5 cases are reported
(Fig. 1). In Romania, Hungary and Slovakia, G1 is almost
the only genotype found (98.0 , 94.1 and 89.9 %, respect-
ively). A considerable percentage of G3 was described in
Macedonia (44.6 %), Slovenia (37.8 %) and Croatia
(35.6 %), while a significant prevalence of G2 was
described only in Albania (20.0 %) and of G4 in
Montenegro (19.6 %) and Albania (16.0 %).
No genotypes distribution data are available from
Bulgaria.
Eastern Europe
The prevalence of HCV infection in this zone, including
Belarus, Estonia, Lithuania, Latvia, Moldova, Russia and
Ukraine, is 3.1 %, ranging between 4.5 % in Moldova and
1.3 % in Belarus, with a viraemic rate estimated at
69.6 % (Table 4). No adult HCV prevalence and/or
viraemic data are available from Estonia.
The predominant genotypes in this area is G1 (68.1 %),
followed by G3 (26.6 %) and G2 (4.3 %). Only a small per-
centage of mixed genotypes and G4 (0.5 %) are reported,
whereas no G5 and G6 cases has been described (Fig. 2).
Only in Latvia G1 is the dominant genetic variant
(89.2 %). A considerable percentage of G3 was described
in Belarus (38.5 %) and Russia (35.1 %).
No genotypes distribution data are available from
Moldova and Ukraine.
Western Europe
The countries studied in this area were Austria, Belgium,
Cyprus, Denmark, Finland, France, Germany, Greece,
Table 1 HCV Seroprevalence and viraemic rate in Europe




Europe, Central 1.2 73.3
Europe, Eastern 3.1 69.6
Europe, Western 0.9 71.0
Total Europe 1.7 71.3
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Iceland, Ireland, Italy, Luxembourg, The Netherlands,
Norway, Portugal, Spain, Sweden, Switzerland and United
Kingdom.
The prevalence of HCV in the general population of
this area is 0.9 %, ranging between 2.0 % in Italy and
0.2 % in The Netherlands, with a viraemic rate estimated
at 71.0 % (Table 5). No representative data concerning
the HCV prevalence from published studies were found
from Iceland.
The predominant genotypes is G1 (55.1 %), followed
by G3 (29.0 %), G2 (8.9 %) and G4 (5.8 %), whereas only
small percentages of G5, G6 and mixed genotypes are
reported (Fig. 3). In Austria, Spain, Germany and Italy
G1 is over the sixty percent of all the genotypes found.
A considerable percentage of G3 was described in some
of the countries of the Northern Europe, as Finland
(46.0 %), United Kingdom (43.8 %), Denmark (43.0 %),
whereas only Italy shows a significant percentage of G2
(26.0 %).
No genotypes distribution data are available from Cyprus.
Discussion and conclusions
Hepatitis C virus (HCV) infection is one of the major
public health burden in Europe, causing an increasing
level of liver-related morbidity and mortality due to the
disease progression [32–38].
The HCV disease paradigm varies by country based
on historical and present risk factors, screening
programs and treatment rates. Individual countries
must consider appropriate country-specific preven-
tion, diagnosis and treatment strategies to reduce the
disease burden represented by HCV. Unfortunately, in
many countries, there is a lack of robust epidemio-
logical data upon which to base these strategies. Many
studies have examined regional HCV infection rates
[39–42], but they have typically focused on quantifying
the anti-HCVprevalence with no attention to HCV
genotypes distribution.
Here we have provided a comprehensive review of
HCV epidemiology studies throughout Europe between
2000 and 2015 with a special care to not base our study
only on available data but instead trying to analyze only
the relevant data. In fact, although HCV prevalence
among blood donors, available in many countries, repre-
sents surely an attractive data source for the large sam-
ple size, all the studies concerning only this subgroup
were excluded because this population, corresponding to
healthy screened adults, is not representative of the total
population. For the same reason, on the contrary,
numerous high risk populations studies (e.g. PWIDs,
haemodialysis patients, cancer patients, etc.) were not
considered too. Finally, all the studies published prior to
2000 were excluded considering the global epidemio-
logical changes that HCV infections has had in the latest
twenty years [43–45].
Studying 33 countries (9 in Central Europe, 6 in
Eastern Europe, and18 in Western Europe), HCV preva-
lence in Europe is estimated at 1.7 % (over 10 million of
HCV infected adults). Our data suggest that the lowest
HCV prevalence estimates are from Western European
countries (0.9 %), while the highest from Eastern Europe
(3.1 %), even if these percentages should probably be ad-
justed in the future given the limited evidentiary sup-
port, especially from some countries in Central and
Eastern European bloc. The main shortcomings of ma-
jority of studies from these areas reside in the fact that
data are often based on surveys conducted in selected
groups [32–34]. Furthermore, many studies are out-
dated and have failed to take into consideration the
influence of some recent drivers such as migratory
Table 2 Prevalence of HCV genotypes in Europe
Continents G1 (%) G2 (%) G3 (%) G4 (%) G5 (%) G6 (%) Mixed
Central Europe 70.0 3.2 21.0 4.9 - 0.1 0.8
Eastern Europe 68.1 4.3 26.6 0.5 - - 0.5
Western Europe 55.1 8.9 29.0 5.8 0.2 0.1 0.8
Total Europe 64.4 5.5 25.5 3.7 0.1 0.1 0.7
Table 3 HCV prevalence/infected population in Central Europe









Central Europe 31 1.2 1188.7 73.3
Bulgaria 3 1.1 67 -
Croatia 1 0.9 38.2 -
Czech
Republic
1 0.7 60 70.0
Hungary 6 0.8 68 84.6
Poland 10 0.9 279 70.0
Romania 5 3.2 575 91.3
Serbia 1 0.5 35.5 -
Slovakia 1 1.4 66 49.2
Slovenia 3 - - 74.6
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movements, including those regarding war refugees
and illegal human trafficking.
No adult HCV prevalence studies were available from
6 countries (1 both in Central and Western Europe and
4 in Eastern Europe), but in order of their contribution,
the studied countries account for over the 80 % of total
European population.
Our analysis shows that the prevalence and number of
HCV infected patients in Europe, if compared to a simi-
lar study concerning the period 1990–2005 and covering
the geographical area of Europe defined by the WHO
(i.e. including the former USSR republics) [5], has
decreased from 2.6 % (95 % uncertainty interval [UI]:
2.4–2.9 %) to 1.7 % (95 % UI: 0.9 %–3.1 %) and from 19
to 13 millions. It is interesting to note that the most
relevant decrease has been observed in Western Europe
(−1.5 %) and Central Europe (− 1.1 %), whereas Eastern
Europe countries register a moderate increase (+0.2 %).
By estimating the total number of HCV RNA positive
infections, our data show that the global average
viraemic rate is at 72.4 % (9.4 millions of HCV RNA
positive cases), varying from 73.3 % in Central Europe to
69.6 % in Eastern Europe (Table 1). It is interesting
notice that some countries, where it is reported an high
anti-HCV prevalence, also have a low viraemic rate. The
most interesting example is Poland where it was found
an anti-HCV prevalence of 1.9 % with a viraemic rate of
31 % (a viraemic prevalence of 0.6 %) [42]. A more
recent study conducted in the same country by using a
confirmatory antibody test has showed an anti-HCV
prevalence of 0.86 % [46]. This example suggests the
need to study viraemic infections since some historically
high antibody prevalence estimates may be influenced by
the use of low sensitive screening HCV tests.
Although these data seems to indicate a general
decrease of HCV infection especially in Western Europe,
a recent modelization has estimated how the numbers of
HCV- mortality will increase in the next decades [15].
The disease progression model took into account the
historical number of HCV infections, the age and gender
distribution, the extent and impact of the movers of the
HCV viraemic pool (i.e. so-called inputs and outputs,
encompassing acute infections progressing to chronicity,
migration movements, treatment uptake succeeding into
viral eradication and deaths), the progression rates
(based on literature data) and the all-cause mortality
data gathered from the Human Mortality Database
adjusted for incremental increases due to drug abuse


















Fig. 1 Genotype distribution in Central Europe
Table 4 HCV prevalence/infected population in Eastern Europe









Eastern Europe 20 3.1 6682 69.6
Belarus 2 1.3 100 69.0
Latvia 3 2.9 73 71.4
Lithuania 2 2.4 42 -
Moldova 2 4.5 130 -
Russia 8 4.1 4932 -
Ukraine 1 3.6 1385 -
Petruzziello et al. Infectious Agents and Cancer  (2016) 11:53 Page 5 of 9
major European countries (i.e. Austria, Belgium, England,
France, Germany, Spain and others) [47]. According to
this model, in the period 2013–2030, the number of
decompensated cirrhosis, the prevalence of HCC in the
general population and the liver-related morbidity rate will
increase in Europe by 80 %, 75 % and 65 %, respectively.
The only exception to this dreaded scenario is represented
by France, where these parameters will decrease by 80 %,
85 % and 75 % in the same period, probably due to the
large use of more potent antivirals.
A low diagnosis rate is obviously a major hurdle to
implement strategies to fight the future health burden of
HCV. As shown recently [15], countries where is avail-
able a centralized registry, such as Austria, France,
Germany and others north Europe countries, tend to
boost the highest diagnosis rates (up to 80 % for Sweden),
while the lowest rates were reported for southern Europe
countries, like Portugal (33 %). An useful strategy of
screening should consider all patients with a history of
exposure via the traditional routes of HCV infection, lim-
iting the number of patients unaware of their infection,
even if this approach is not useful to contain the increas-
ing rate of mortality HCV related. For this purpose it
would be necessary a more accurate analysis of the distri-
bution of HCV genotypes and of their circulation in
Europe, whose lack of data is one of the major health
problems in Europe.
Concerning the genotype distribution, G1 accounts for
64.4 % of all HCV infections among adults making it the
most common, either in Central Europe (70.0 %) and in
Western Europe (55.1 %). Even if here not reported,
many data suggest that the subtypes 1a/1b ratio is
dependent on patient age and transmission route, with a
major prevalence of subtype G1b in older patients and
of subtype G1a in PWIDs [48, 49].
G3 is the second most common genotype (25.5 %),
ranging from 29.0 % in Western Europe, 26.0 % in
Eastern and 21.0 % in Central Europe. This is also one
of the most challenging genotypes for therapy, since only
sofosbuvir and daclatasvir are licensed for its treatment,













Fig. 2 Genotype distribution in Eastern Europe
Table 5 HCV prevalence/infected population in Western Europe









Western Europe 478 0.9 3339 71.0
Austria 26 0.5 36 73.4
Belgium 15 0.9 86 80.0
Cyprus 2 0.6 5 71.4
Denmark 8 0.7 33 62.2
Finland 4 0.7 31 -
France 104 0.6 197 65.0
Germany 56 0.6 401 66.7
Greece 25 1.9 178 -
Ireland 7 1.1 40 75.0
Italy 124 2.0 1048 73.3
Luxembourg 1 0.9 4 -
The Netherlands 1 0.2 31 -
Norway 5 0.7 29 79.5
Portugal 4 1.8 164 -
Spain 51 1.7 688 68.6
Sweden 18 0.7 53 77.0
Switzerland 12 1.5 105 -
United Kingdom 15 0.6 210 68.5
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progression and, as G1, higher prevalence of severe stea-
tosis and hepatocellular carcinoma. G3 has been diag-
nosed more frequently in drug consumers in certain
areas especially in West European countries [50, 51].
G2 is the third most frequent genotype with percent-
ages ranging from 8.9 % in Western Europe to 3.2 % in
Central Europe [19, 52–54]. It is significantly associated
to females, nosocomial infection or dental therapy and is
mostly detected in older patients. Higher proportions of
G2 were found in Sweden, Finland, Russia and in some
of the ex soviet republics, probably in accordance to the
Asian genotypes distribution, and in Italy [55, 56],
especially in Southern areas [57, 58]. G2 subtype 2c was
probably introduced in Italy as a result of population
movements during Italian colonialism at the end of the
19th century, and it did not spread there through intra-
venous drug use [59].
G4, instead, traditionally associated to Central Africa and
the Middle East [5, 13, 54] and mainly related to sexual
practices, especially in MSM, and in HIV-coinfected pa-
tients [19], shows an average European proportion of
around 3.7 %, ranging from 5.8 % in Western Europe and
4.9 % in Central Europe and only small percentage in
Eastern Europe (0.5 %). A high prevalence of this
genotype has been described in Belgium, Greece and
The Netherlands (14.0 %, 13.9 % and 10.5 %, respectively),
but also in France and Spain (9.2 % and 8.0 %), prob-
ably as consequence of three concomitant processes:
increase in immigration from Northern and Central
Africa, the use of drugs, and the introduction of G4
subtype d viruses into European networks of MSM
and injection drug users [60].
Genotypes 5 and 6 were detected in extremely low
frequencies and no association with independent epi-
demiological parameters was found.
It is necessary to clarify that in this study it was not
possible to find a significant association between distri-
bution of HCV genotypes and transmission route, since
these data were clearly documented only for 25 % of the
studies. Furthermore, a clear classification of each geno-
type in subtypes was found available only for 40 % of the
selected studies. This lack of data has avoided a reliable
subtypes distribution analysis, and also of “unresolved”
or “mixed” infections that were not always clearly sepa-
rated from double infections (unmistakable co- existence
of two or more HCV strains).
In conclusion, HCV epidemiology shows a high vari-
ability across Europe, exhibiting a dynamic process influ-
enced by traditional genotypes prevalence and evolving
transmission trends. The early-nineties epidemics of GTs
1b and 2, mainly related to nosocomial transmission,
have been partially replaced by a scenario of GTs 1a, 3
and 4 where PWIDs and high-risk sexual practices are
the main risk factor for HCV transmission [61, 62]. In
fact, despite eradication of transmission by blood prod-






















Fig. 3 Genotype distribution in Western Europe
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countries, especially in Eastern Europe, probably due to
the increase of PWID rate. Furthermore, other factors
may also influence epidemiologic trend of HCV infec-
tion within the next years and lead to changes in its
epidemiology, as the role of past and current immigra-
tion, the increase in sex/drug consume-tourism, HCV
re-infections rates in IVDA, generation of new (recom-
binant) GTs, as well as selection of certain GTs by the
current DAAs [63–65].
This review is one of the first attempt for the collec-
tion of European HCV data to provide reliable informa-
tion about the current genotype prevalence situation,
and it is also a call to join efforts and encourage further
observational studies on HCV genotype prevalence at
supra- national level to gain reliable knowledge on the
epidemiology of HCV infection. Stronger national and
international efforts, including a more massive collection
of data especially on risk groups and the institution of a
central register to monitor the national HCV diagnosis
rates, could surely introduce an appropriate strategyto
limit HCV infection in Europe.
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